About
About Pandion
Leadership
Board of Directors
Advisors
Key Collaborations
Taking Flight Blog
Our Science
TALON™ Platform
What Makes Us Different
Posters & Presentations
Pipeline
Our Pipeline
IL-2 Mutein
PD-1 Agonism
Culture
Our Culture
Community Activities
Investors & News
Careers
Contact
POSITIVE PHASE 1A CLINICAL DATA: PT101 was well-tolerated and demonstrated proof of mechanism in healthy volunteers
More
Our TALON™ Platform
is built to create modular protein therapeutics for systemic and local immune regulation
Our pipeline
is built to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases
latest news
January 4, 2021: Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
December 3, 2020: Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
December 3, 2020: Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
